Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study

Annals of Oncology

Volumn 18, Issue 1, 2007, Pages 77-81

  André, Thierry ^a,g   Tournigand, C ^b,g   Mineur, L ^c,g   Fellague Chebra, R ^g   Flesch, M ^d,g   Mabro, M ^e,g   Hebbar, M ^f,g   Postel Vinay, S ^a   Bidard, F C ^a   Louvet, C ^b,g   de Gramont, A ^b,g  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSTITUT SAINTE CATHERINE   (France)

^d Devron Hospital   (France)

^e FOCH HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g Multidisciplinary Cooperative Oncology Group   (France)

Author keywords

5 fluorouracil; Celecoxib; Colorectal metastatic cancer; Oxaliplatin

Indexed keywords

CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON SURGERY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPIGASTRIC PAIN; EPISTAXIS; FEMALE; GASTRITIS; HAND FOOT SYNDROME; HUMAN; LARYNX SPASM; MAINTENANCE THERAPY; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PYRAZOLES; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846490807     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl336     Document Type: Article

References (24)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
3. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24: 394-400.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
5. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
6. Maindrault-Goebel F, de Gramont A, Louvet C et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000; 11: 1477-1483.
7. Maindrault-Goebel F, Tournigand C, Andre T et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15: 1210-1214.
8. Maughan T, James R, Kerr D et al. Continuous vs intermittant chemotherapy for advanced colorectal cancer: Preliminary results of the MRC Cr06b randomised trial. Lancet 2003; 361: 457-464.
9. Raoul JL, Trivin F, Egreteau J, Boucher E. Chimiothérapie des cancers colorectaux métastatiques: Pourquoi ne pas arrêter quand elle marche? Gastro Clin Biol 2005; 28, HS1, A221.
10. Hull MA, Fenwick SW, Chapple KS et al. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 2000; 18: 21-27.
11. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
12. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
13. Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
14. Oshima M, Murai N, Kargman S et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-1740.
15. Sheng H, Shao J, Kirkland SC et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-2259.
16. Reddy BS, Hirose Y, Lubet R et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293-297.
17. Yao M, Kargman S, Lam EC et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-592.
18. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: A population-based study. Arch Intern Med 1999; 159: 161-166.
19. Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
20. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
21. Labianca R, Floriani I, Cortesi E et al. Alternating versus continuous 'FOLFIRI' in advanced colorectal cancer (ACC); a randomized 'GISCAD' study. Proc Am Clin Oncol 2006; 24: 147s (Abstr 3505).
22. Alexopoulos CG, Kotsori AA. Continuous versus intermittent chemotherapy in metastatic colorectal cancer. Proc Am Clin Oncol 2006; 24: 166s (Abstr 3582).
23. Maindrault-Goebel F, Lledo G, Chibaudel B et al. GERCOR OPTIMOX 2. A large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc Am Clin Oncol 2006; 24: 147s (Abstr 3504).
24. Plantade A, Afchain P, Tournigand C et al. Chemothearpy-free intervals (CFI) in patients with metastatic colorectal cancer. Proc Am Clin Oncol 2006; 24: 166s (Abstr 3581).